Florence Boissiere-Michot
Overview
Explore the profile of Florence Boissiere-Michot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
799
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jacot W, Chateau M, Thezenas S, Guiu S, Firmin N, Lafont V, et al.
Cancer Med
. 2025 Mar;
14(5):e70615.
PMID: 40059728
Introduction: Triple-Negative Breast Cancer (TNBC) is an aggressive breast cancer subtype, in which targeting the Trophoblast cell-surface antigen-2 (Trop-2), using antibody-drug conjugates (ADC), results in significant clinical improvement. However, clinicopathological...
2.
Constanzo J, Parach A, David T, Karam J, Bruchertseifer F, Morgenstern A, et al.
J Nucl Med
. 2025 Feb;
PMID: 40015918
Preclinical and clinical studies increasingly show that the immune response plays a major role in radiotherapy. Here, we investigated the role of major histocompatibility complex class I (MHC-I) molecules recognized...
3.
Boissiere-Michot F, Chateau M, Thezenas S, Lafont V, Crapez E, Sharma P, et al.
Front Immunol
. 2024 Dec;
15:1507371.
PMID: 39723208
Background: In triple-negative breast cancer (TNBC), the most immunogenic breast cancer type, tumor-infiltrating lymphocytes (TILs) are an independent prognostic factor. Tertiary lymphoid structures (TLS) are an important TILs source, but...
4.
Massa D, Vernieri C, Nicole L, Criscitiello C, Boissiere-Michot F, Guiu S, et al.
J Natl Cancer Inst
. 2024 Jul;
116(12):1914-1927.
PMID: 39083015
Background: The cutoff of <1% positive cells to define estrogen receptor (ER) negativity by immunohistochemistry (IHC) in breast cancer (BC) is debated. We explored the tumor immune microenvironment and gene-expression...
5.
Sfeir N, Kajdan M, Jalaguier S, Bonnet S, Teyssier C, Pyrdziak S, et al.
Mol Oncol
. 2024 Mar;
18(6):1510-1530.
PMID: 38459621
The transcription factor receptor-interacting protein 140 (RIP140) regulates intestinal homeostasis and tumorigenesis through Wnt signaling. In this study, we investigated its effect on the Notch/HES1 signaling pathway. In colorectal cancer...
6.
du Roure P, Lajoie L, Mallavialle A, Alcaraz L, Mansouri H, Fenou L, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38290768
Introduction: Triple-negative breast cancer (TNBC) prognosis is poor. Immunotherapies to enhance the antibody-induced natural killer (NK) cell antitumor activity are emerging for TNBC that is frequently immunogenic. The aspartic protease...
7.
Wild C, Garrido F, Dannecker C, Kopke M, Chateau M, Boissiere-Michot F, et al.
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894319
There exists a variety of studies about tumor-infiltrating immune cells (TIICs) in cervical cancer, but their prognostic value in correlation with the histopathological subtype has never been investigated. Therefore, the...
8.
Cherradi S, Garambois V, Marines J, Andrade A, Fauvre A, Morand O, et al.
Cell Biosci
. 2023 Apr;
13(1):72.
PMID: 37041570
Background: Tumor resistance is a frequent cause of therapy failure and remains a major challenge for the long-term management of colorectal cancer (CRC). The aim of this study was to...
9.
Boissiere-Michot F, Chateau M, Thezenas S, Guiu S, Bobrie A, Jacot W
Front Immunol
. 2022 Dec;
13:1058424.
PMID: 36544779
Background: T cell immunoreceptor with Ig and ITIM domains (TIGIT) interacts with poliovirus receptor (PVR) to contribute to cancer immune escape. Recently, TIGIT and PVR have been identified as promising...
10.
Alcaraz L, Mallavialle A, Mollevi C, Boissiere-Michot F, Mansouri H, Simony-Lafontaine J, et al.
Int J Cancer
. 2022 Nov;
152(6):1243-1258.
PMID: 36346290
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and lacks specific targeted therapeutic agents. The current mechanistic evidence from cell-based studies suggests that the matricellular protein SPARC...